J. L. Garnier

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Laurent Arnould, M Gelly, Frédérique Penault‐Llorca et al. · British Journal of Cancer · 2006 · 529 citations · Full text

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

Nöel Milpied, B. Vasseur, Nathalie Parquet et al. · Annals of Oncology · 2000 · 376 citations · Full text

Lymphoid Neoplasia, Transplantation, Immunosuppressive Therapy +10

Sirolimus Conversion for Patients with Posttransplant Kaposi's Sarcoma

Célèste Lebbé, Sylvie Euvrard, Benoı̂t Barrou et al. · American Journal of Transplantation · 2006 · 130 citations · Full text

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

Bruno Coudert, Laurent Arnould, L. Moreau et al. · Annals of Oncology · 2005 · 95 citations

Her2-overexpressing Stage Ii, Oncology, Breast Oncology +5

Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes.

Rosemary Rochford, M V Hobbs, J. L. Garnier et al. · Proceedings of the National Academy of Sciences · 1993 · 57 citations · Full text